Liquidia Corporation $LQDA Holdings Decreased by Opaleye Management Inc.

Opaleye Management Inc. reduced its stake in Liquidia Corporation (NASDAQ:LQDA) by 3.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,447,500 shares of the company’s stock after selling 97,500 shares during the quarter. Liquidia comprises about 17.7% of Opaleye Management Inc.’s portfolio, making the stock its largest holding. Opaleye Management Inc. owned about 2.73% of Liquidia worth $195,139,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. WINTON GROUP Ltd acquired a new stake in shares of Liquidia during the second quarter worth $335,000. Arizona State Retirement System raised its stake in Liquidia by 5.4% in the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after acquiring an additional 900 shares during the last quarter. Nykredit A S acquired a new stake in Liquidia during the 2nd quarter worth about $177,000. Corient Private Wealth LP purchased a new stake in Liquidia during the 2nd quarter valued at about $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Liquidia during the 2nd quarter valued at about $1,236,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Stock Down 1.8%

LQDA stock opened at $67.85 on Friday. The stock has a market capitalization of $6.07 billion, a P/E ratio of 49.53 and a beta of 0.53. The firm has a 50-day simple moving average of $77.71 and a 200-day simple moving average of $59.21. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. Liquidia Corporation has a 52 week low of $21.15 and a 52 week high of $93.61.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same period in the prior year, the business posted ($0.49) earnings per share. The company’s quarterly revenue was up 1842.1% compared to the same quarter last year. Equities analysts forecast that Liquidia Corporation will post 2.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on LQDA shares. Piper Sandler set a $129.00 price objective on Liquidia in a research note on Friday, July 24th. Wall Street Zen lowered shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Bank of America lifted their price objective on shares of Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Stephens set a $130.00 price objective on shares of Liquidia in a research note on Friday, July 24th. Finally, BTIG Research boosted their target price on shares of Liquidia from $109.00 to $111.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $98.08.

Insider Transactions at Liquidia

In other Liquidia news, Director Stephen M. Bloch sold 100,000 shares of the firm’s stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $89.48, for a total value of $8,948,000.00. Following the transaction, the director owned 501,477 shares in the company, valued at approximately $44,872,161.96. This trade represents a 16.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Katherine Rielly-Gauvin sold 18,393 shares of Liquidia stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $72.23, for a total transaction of $1,328,526.39. Following the sale, the director directly owned 44,637 shares in the company, valued at approximately $3,224,130.51. This trade represents a 29.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 790,089 shares of company stock valued at $60,549,874. Insiders own 25.60% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.

Liquidia’s lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.